| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation expense | 7,946,529 |
| Net loss | -30,996,623 |
| Amortization of operating lease right-of-use asset | 152,212 |
| Issuance of common stock for services | 0 |
| Prepaid expenses | -1,386,824 |
| Operating lease liability | -167,911 |
| Inventory | 8,940,201 |
| Accrued compensation | 1,481,023 |
| Accrued expenses | 8,506,648 |
| Accounts payable | 5,166,831 |
| Depreciation | 0 |
| Deferred income tax expense | 792,720 |
| Net cash used in operating activities | -14,671,948 |
| Repayment of advance from employee | 300,000 |
| Proceeds from note payable and advance from employee | 1,300,000 |
| Proceeds from sale of series a preferred stock | 100 |
| Net proceeds from common stock offerings | 16,509,194 |
| Redemption of series a preferred stock | 100 |
| Net cash provided by financing activities | 17,509,194 |
| Net change in cash and cash equivalents | 2,837,246 |
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc. (CTXR)